Candriam S.C.A. Ultragenyx Pharmaceutical Inc. Transaction History

Candriam S.C.A.

$18.4 Billion
Q3 2025

A detailed history of Candriam S.C.A. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 754,714 shares of RARE stock, worth $25 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

754,714

Previous 526,267 43.41%

Holding current value

$25 Million

Previous $19.1 Million 18.64%

% of portfolio

0.12%

Previous 0.11%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 05, 2025	BUY	$26.31 - $41.44 $6.01 Million - $9.47 Million	228,447 Added 43.41%	754,714 $22.7 Million
Q2 2025 Aug 08, 2025	SELL	$31.06 - $39.3 $6.27 Million - $7.93 Million	-201,750 Reduced 27.71%	526,267 $19.1 Million
Q1 2025 May 14, 2025	BUY	$36.21 - $45.78 $1.95 Million - $2.46 Million	53,760 Added 7.97%	728,017 $26.4 Million
Q4 2024 Feb 06, 2025	SELL	$42.07 - $57.72 $1.63 Million - $2.24 Million	-38,835 Reduced 5.45%	674,257 $28.4 Million
Q3 2024 Nov 13, 2024	BUY	$40.21 - $59.36 $971,071 - $1.43 Million	24,150 Added 3.51%	713,092 $39.6 Million

Q2 2024 Aug 05, 2024	BUY	$37.42 - $51.61 $6.41 Million - $8.84 Million	171,345 Added 33.1%	688,942 $28.3 Million
Q1 2024 May 03, 2024	BUY	$43.02 - $53.69 $15.9 Million - $19.8 Million	369,117 Added 248.6%	517,597 $24.2 Million
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $3.14 Million - $4.87 Million	99,000 Added 200.08%	148,480 $7.1 Million
Q2 2023 Aug 08, 2023	SELL	$37.35 - $52.15 $416,639 - $581,733	-11,155 Reduced 18.4%	49,480 $2.28 Million
Q1 2023 May 12, 2023	BUY	$36.99 - $48.71 $412,623 - $543,360	11,155 Added 22.54%	60,635 $2.43 Million
Q2 2021 Jul 20, 2021	SELL	$92.19 - $115.71 $4.51 Million - $5.66 Million	-48,949 Reduced 49.73%	49,480 $4.72 Million
Q4 2020 Jan 22, 2021	BUY	$84.4 - $177.39 $8.31 Million - $17.5 Million	98,429 New	98,429 $13.6 Million
Q2 2020 Jul 23, 2020	SELL	$46.91 - $78.22 $5.7 Million - $9.5 Million	-121,500 Closed	0 $0
Q4 2019 Jan 21, 2020	SELL	$36.08 - $45.83 $685,520 - $870,770	-19,000 Reduced 13.52%	121,500 $5,000
Q3 2019 Oct 21, 2019	BUY	$42.5 - $63.11 $637,500 - $946,650	15,000 Added 11.95%	140,500 $6,000
Q2 2019 Aug 01, 2019	BUY	$54.93 - $74.36 $549,300 - $743,600	10,000 Added 8.66%	125,500 $7.93 Million
Q4 2018 Feb 14, 2019	BUY	$38.89 - $77.3 $93,336 - $185,520	2,400 Added 2.12%	115,500 $5.02 Million
Q3 2018 Nov 07, 2018	BUY	$71.81 - $90.15 $2.02 Million - $2.53 Million	28,100 Added 33.06%	113,100 $8.63 Million
Q2 2018 Aug 14, 2018	SELL	$48.54 - $85.31 $291,240 - $511,860	-6,000 Reduced 6.59%	85,000 $6.53 Million
Q1 2018 May 09, 2018	BUY	$44.33 - $58.52 $753,610 - $994,840	17,000 Added 22.97%	91,000 $4.64 Million
Q4 2017 Feb 07, 2018	BUY	$43.54 - $57.32 $609,560 - $802,480	14,000 Added 23.33%	74,000 $3.43 Million
Q3 2017 Nov 03, 2017	BUY	$49.79 - $66.32 $2.99 Million - $3.98 Million	60,000	60,000 $3.2 Million

Others Institutions Holding RARE

# of Institutions

348

Shares Held

88.2M

Call Options Held

2.19M

Put Options Held

1.04M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.32B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account